This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression

This study has been completed.
Information provided by (Responsible Party):
Corcept Therapeutics Identifier:
First received: September 2, 2005
Last updated: February 14, 2012
Last verified: February 2012
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress, triggering a healthy stress response. People who suffer from psychotic major depression may have unusually high levels of cortisol circulating within them or abnormal patterns of cortisol levels, overloading the stress response mechanism and causing symptoms of psychosis such as delusional thoughts or hallucinations. If Corlux can keep the body's cortisol receptors from being overloaded, the stress response system may return to normal function, which may result in improvement of symptoms. The purpose of this 56 day study is to learn the safety and effectiveness of Corlux in patients who have been diagnosed with psychotic major depression (PMD).

Condition Intervention Phase
Major Depressive Disorder Drug: Mifepristone Drug: placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: An International, Double-Blind, Placebo-Controlled, Study of the Efficacy and Safety of CORLUX™ (Mifepristone) vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Psychotic Major Depression (PMD)

Resource links provided by NLM:

Further study details as provided by Corcept Therapeutics:

Primary Outcome Measures:
  • The change in a measure of psychosis [ Time Frame: screening and on Days 0, 7, 14, 28, 42, and 56 ]

Secondary Outcome Measures:
  • The change in a measure of depression [ Time Frame: screening and on Days 0, 7, 14, 28, 42, and 56 ]

Enrollment: 247
Study Start Date: May 2005
Study Completion Date: July 2006
Primary Completion Date: July 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: mifepristone 600 mg Drug: Mifepristone
Placebo Comparator: matching placebo Drug: placebo


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Are 18 to 75 years of age
  • Have a diagnosis of major depressive disorder with psychotic features (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM IV] 296.24 or 296.34)
  • Are able to provide written informed consent.

Exclusion Criteria:

  • Have a major medical problem
  • Have previously participated in a Corlux (C-1073, mifepristone) clinical trial
  • Have a history of an allergic reaction to Corlux (C-1073, mifepristone).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00146523

Georgy Koychev M.D.
Sofia, Bulgaria
Luchezar G Hranov M.D.
Sofia, Bulgaria
Svetlozar H Haralanov Ph.D.
Sofia, Bulgaria
Vihra Milanova M.D.
Sofia, Bulgaria
Georgi Popov M.D.
Varna, Bulgaria
Pavo Filakovic M.D./Ph.D.
Osijek, Croatia
Ljiljana Moro M.D./Ph.D.
Rijeka, Croatia
Goran Dodig M.D./Ph.D.
Split, Croatia
Dubravka Kocijan-Hercigonja M.D.
Zagreb, Croatia
Miro Jakovljevic M.D.
Zagreb, Croatia
Vera Folnegovic-Smalc M.D./Ph.D.
Zagreb, Croatia
Former Serbia and Montenegro
Ivana Timotijevic M.D.
Belgrade, Former Serbia and Montenegro
Jelena Martinovic M.D.
Belgrade, Former Serbia and Montenegro
Vladimir Diligenski M.D.
Belgrade, Former Serbia and Montenegro
Vladimir Paunovic M.D.
Belgrade, Former Serbia and Montenegro
Dragana Ignjatovic-Ristic M.D.
Kragujevac, Former Serbia and Montenegro
Ratomir Lisulov M.D.
Novi Sad, Former Serbia and Montenegro
Mihai Dumitru Gheorge
Bucharest, Romania
Aurel Nirestean M.D./Ph.D.
Targu Mures, Romania
Sponsors and Collaborators
Corcept Therapeutics
Study Director: Katherine Beebe, PhD Corcept Therapeutics
  More Information

Additional Information:
Responsible Party: Corcept Therapeutics Identifier: NCT00146523     History of Changes
Other Study ID Numbers: C-1073-09
Study First Received: September 2, 2005
Last Updated: February 14, 2012

Keywords provided by Corcept Therapeutics:
Psychotic Major Depression
Major Depression

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Mental Disorders
Psychotic Disorders
Behavioral Symptoms
Mood Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Abortifacient Agents, Steroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Contraceptives, Postcoital, Synthetic
Contraceptives, Postcoital
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents
Menstruation-Inducing Agents processed this record on September 19, 2017